ELAB (Elevai Labs Inc.) Future Price to Earnings

ELAB (elevaiskincare.com) - company brandmark

Elevai Labs Inc. (ELAB) possesses strong pricing power in the premium exosome serum segment, which creates a dependency on expensive marketing that drains liquidity. This trend is evident in the projected P/E ratio changes for the company on GURU.Markets, where the value of 0.00 captures the metric level. Business prospects rely on sales growth within clinics and the expansion of the biomedical patent portfolio.

Forward P/E Multiple: elevaiskincare.com (ELAB) for 02/21/2024 - 11/15/2026

Elevai Labs Inc. (ELAB) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Quotes Elevai Skincare|ELAB - Fair Value Consensus
- business market valuation indicators:
Market Value Elevai Labs Inc.|ELAB - Company Buyout Price
- balance sheet equity data:
Net Assets per Single Share Elevai Labs|ELAB - Book Capitalization|Market Capitalization to Book Value Ratio elevaiskincare.com|ELAB - Company Total Asset Base
- debt and liquidity details:
Debt to Equity Elevai Labs Inc.|ELAB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Elevai Corp|ELAB - Company Cumulative Debt|Debt to Book Capitalization Ratio Elevai Corp|ELAB - Company Long-Term Debt|Company Short-Term Debts Elevai Labs|Quick Liquidity Indicator elevaiskincare.com
- company profitability and valuation multiples indicators:
ELAB - Company Net Income|Projected Future Earnings Elevai Labs Inc.|ELAB - P/E Multiple|Forward P/E Multiple elevaiskincare.com|ELAB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Elevai Labs|ELAB - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Elevai Labs|ELAB - Earnings per share for the last twelve months|Quarterly EPS earnings growth elevaiskincare.com|ELAB - Earnings growth in current year|Earnings growth forecast for next year Elevai Labs Inc.
- sales volume and revenue indicators:
ELAB - Company Revenue|Company Projected Revenue Elevai Corp|ELAB - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Elevai Labs|ELAB - Revenue Dynamics YoY (Last Twelve Months)
Analysis of all company metrics:ELAB Elevai Skincare
Signature product of Elevai Corp

For Elevai Labs Inc., which focuses on exosomal biotechnologies, this indicator reflects market expectations for capitalization relative to projected earnings. By analyzing changes in the company's forward P/E ratio, investors assess the growth premium and the risk of overpayment given its narrow niche specialization. The multiplier's dynamics allow for the quantitative determination of the asset's value expansion phase as the brand expands into international markets.

Competing companies

Projected Price to Earnings KRYS (Krystal Corp)|APGE (Apogee Corp) - Future Price to Earnings Multiple|Future Price to Earnings arcutis.com ARQT|Market Cap to Projected Earnings vcel.com (VCEL)|ORKA - Future Price to Earnings|SMTI - Forward P/E Multiple|DBVT: Forward P/E Multiple|SLSN - Market Cap to Projected Earnings|Future Price to Earnings Journey Medical Corporation|Price to Future Earnings Ratio FBRX (Forte Biosciences, Inc.)|Forward P/E Multiple EMPG|Market Cap to Projected Earnings Sol-Gel Technologies Ltd|reviveprocare.com - Projected Price to Earnings|Medicus Pharma Limited (MDCX) - Projected Price to Earnings Ratio|VRCA - Future Price to Earnings|hoththerapeutics.com - Market Cap to Future Earnings Ratio|BFRI: Forward P/E Multiple|Projected Price to Earnings Ratio VYNE Therapeutics (VYNE)|Future Price to Earnings sonomapharma.com|Price to Future Earnings Ratio QNRX (Quoin Pharmaceuticals Ltd.)|Forward P/E Multiple AZTR|Market Cap to Future Earnings Ratio DRMA|Forward P/E Multiple RVNC (Revance Therapeutics Inc)